Compare Mesoblast Limited (MESO) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs BlackRock TCP Capital Corp — how do they compare? Mesoblast Limited trades at $16.38 (market cap $2.17B), while BlackRock TCP Capital Corp trades at $3.24 (market cap $270.17M). The key difference: Mesoblast Limited is far larger — about 8× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays a 26.09% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | TCPC | |
|---|---|---|
Market Cap | $2.17B | $270.17M |
Sector | Technology | Financials |
52-Week High | $20.96 | $7.64 |
52-Week Low | $12.88 | $3.14 |
Enterprise Value | $2.17B | — |
Dividend Yield | — | 26.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $36 million for Ryoncil, showing strong commercial progress, but maintains a net income margin of -144.33% with significant losses. Recent news highlights pivotal Phase 3 trial milestones for chronic low back pain treatment and a $50 million non-dilutive financing draw.
Outlook is mixed: bullish analyst sentiment and clinical advancements offer upside potential, but high cash burn and persistent losses pose substantial risks. Investors should weigh the company's growth trajectory against its financial sustainability and regulatory milestones.
TCPC trades at $3.21, down 3.02% today, with a bearish technical signal from moving averages. The company reported negative revenue and net losses in 2025, though it beat Q1 2026 EPS estimates. A dividend of $0.17 per share is scheduled for June 30, 2026. Analyst consensus is mixed, with 31% buy ratings but 54% hold, reflecting caution amid financial challenges and an ongoing legal investigation into fiduciary duties.
The outlook remains cautious due to persistent negative earnings and revenue trends, with profitability metrics like ROE at -18.74% indicating weak shareholder returns. Risks include the shareholder lawsuit and competitive pressures in the BDC sector. Near-term focus is on the Q2 2026 earnings report due August 6, 2026, which could influence sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
